| Date | Title | Description |
| 03.03.2026 | Diversity will define the next era of biotech infrastructure | - |
| 19.12.2025 | The rise and impact of AI in Biotechnology and Healthcare | - |
| 25.06.2024 | 7 Latest Trends around AI Agents by Artur Kurasiński | The post was originally published in Polish on Artur’s LinkedIn profile. Artur kindly agreed that we repost what we think is of great value to our readers. Specialization. In the coming months, we will see a shift towards more specialized A... |
| 21.06.2023 | Sanofi Goes All-In On AI | Chief Executive Officer of French pharmaceutical giant Sanofi, Paul Hudson, Paris, September 8, ... [+] 2021. (Photo by JOEL SAGET / AFP) (Photo by JOEL SAGET/AFP via Getty Images)AFP via Getty Images |
| 14.10.2022 | What is medical artificial intelligence (AI)? | Did you miss a session from MetaBeat 2022? Head over to the on-demand library for all of our featured sessions here.
Table of contents
Risks and rewards
What are the challenges of medical AI?
What are the opportunities for medical AI?
What ... |
| 06.09.2022 | 6 AI companies disrupting healthcare in 2022 | Were you unable to attend Transform 2022? Check out all of the summit sessions in our on-demand library now! Watch here.
Investments in AI-enabled healthcare have exploded over the past few years. But even with belt-tightening in 2022, digi... |
| 12.01.2021 | StemoniX to Participate in Biotech Showcase(TM) Digital 2021 | Maple Grove, Minnesota--(Newsfile Corp. - January 11, 2021) - StemoniX, a biotech company changing how new drugs are discovered, announced today their participation at the 2021 Biotech Showcase™ being held January 11-15th as part of OrganAi... |
| 06.10.2020 | Atomwise : Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosis | Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today $2.3M in grant funding for AI-based discovery of antimalarial and anti-tuberculosis therapies from the Bill & Melinda Gates Fo... |
| 06.10.2020 | Atomwise Receives a $2.3M Grant |
SAN FRANCISCO, CA, Atomwise announced today $2.3M in grant funding for AI-based discovery of antimalarial and anti-tuberculosis therapies.
>> Click here for more funding data on Atomwise
>> To export Atomwise funding data to... |
| 10.09.2020 | Analysis: August Health IT M&A Activity; Public Company Performance | – Healthcare Growth Partners’ (HGP) summary of Health IT/digital health mergers & acquisition (M&A) activity, and public company performance during the month of August 2020.
M&A is back and the velocity of the rebound has outpac... |
| 14.08.2020 | AI-Based Drug Discovery Company Atomwise Secures $123 Million | Atomwise — a company that is deciphering human disease via the largest AI-drug discovery portfolio — announced that it has raised $123 million in an oversubscribed Series B financing
Atomwise — a company that is deciphering human disease vi... |
| 14.08.2020 | Atomwise raises $123M to expand AI-powered drug design efforts
W h i t e p a p e r
Weighing the Costs: | The artificial intelligence-powered drug designer Atomwise has raised $123 million in venture capital funding, to both scale up its platform and its partnerships with large biopharma companies, and to begin developing its own pipeline of pr... |
| 14.08.2020 | Atomwise raises $123M to expand AI-powered drug design efforts | The artificial intelligence-powered drug designer Atomwise has raised $123 million in venture capital funding, to both scale up its platform and its partnerships with large biopharma companies, and to begin developing its own pipeline of pr... |
| 14.08.2020 | Canada’s Atomwise secures 163M CAD in Series B funding | The AI-driven drug discovery platform was founded in 2012 by Abraham Heifets, Alexander Levy and Dr. Izhar Wallach and was earlier known as Chematria. It was initially a part of University of Toronto’s incubator before associating with Y Co... |
| 12.08.2020 | Atomwise raises $163 million CAD Series B | Atomwise, which operates an artificial intelligence (AI)-based drug discovery platform, has raised $163 million CAD ($123 million USD) in what it called an oversubscribed Series B financing round.
“We will be able to leverage this to develo... |
| 12.08.2020 | Tencent-backed US drug discovery firm Atomwise closes $123m Series B round | Premium
Atomwise, which uses artificial intelligence for structure-based small molecule drug discovery, has raised $123 million in an oversubscribed Series B round, according to a company statement on Tuesday. The San Francisco-based firm s... |
| 11.08.2020 | Drug discovery company Atomwise lands $123M in Series B funding | |
| 11.08.2020 | Designing Better Drugs: Atomwise Lands $123M To Advance AI Drug Discovery | - |
| 11.08.2020 | Designing Better Drugs: Atomwise Lands $123M To Advance AI Drug Discovery | 30 Shares Email Facebook Twitter LinkedIn
Atomwise, which is using artificial intelligence for small molecule drug discovery, received a cash infusion of $123 million in an oversubscribed Series B financing.
Subscribe to the Crunchbase Dail... |
| 11.08.2020 | Sillicon Valley tech startup Atomwise scores $123 million for its AI drug discovery platform | Researchers and companies struggle with access to AI-based drug discovery technology, due to overall cost and lack of expertise — something which requires computational scientists, drug discovery experts, software and systems engineers for ... |
| 11.08.2020 | Atomwise Raises $123M in Series B Financing | Atomwise, a San Francisco, CA-based company deciphering human disease via an AI-drug discovery portfolio, closed a $123m Series B financing round.
The round, brings the total amount of capital raised to date to almost $175m, was led by B Ca... |
| 11.08.2020 | Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil | Atomwise, the company deciphering human disease via the largest AI-drug discovery portfolio, announced today that it has closed $123 million in an oversubscribed Series B financing led by B Capital Group and Sanabil Investments. The funding... |
| 11.08.2020 | Designing Better Drugs: Atomwise Lands $123M To Advance AI Drug Discovery | 32 Shares Email Facebook Twitter LinkedIn
Atomwise, which is using artificial intelligence for small molecule drug discovery, received a cash infusion of $123 million in an oversubscribed Series B financing.
Subscribe to the Crunchbase Dail... |
| 11.08.2020 | Atomwise Raises $123 Million in Series B | - |
| 11.08.2020 | Atomwise raises $123 million to accelerate drug discovery with AI | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Atomwise, a startup using AI to accelerate drug d... |
| 11.08.2020 | Atomwise Receives $123M Series B |
SAN FRANCISCO, CA, Atomwise has closed $123 million in an oversubscribed Series B round.
>> Click here for more funding data on Atomwise
>> To export Atomwise funding data to PDF and Excel, click here
Atomwise, the compan... |
| 11.08.2020 | Atomwise’s machine learning-based drug discovery service raises $123 million | With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializi... |
| 11.08.2020 | Atomwise raises $123 million to accelerate drug discovery with AI | Atomwise, a startup using AI to accelerate drug discovery, today secured $123 million in funding. A spokesperson said the funds will enable the startup to scale its technology and team as it expands its portfolio of joint ventures with rese... |
| 02.10.2019 | Fred Hutch spinout SEngine raises $5.1M to test cancer treatment drugs against a patient’s tumors | SEngine tests how safe and effective various cancer drugs are against a patient’s tumor. Each well in the tray pictured above could hold a tiny version of a tumor and a unique drug or combination of drugs. (SEnginge Photo)
Seattle startup S... |
| 16.09.2019 | YC and Ginkgo Bioworks announce new partnership for synthetic biology startups | Ginkgo Bioworks was the first bio company YC funded, back in summer 2014, which makes us especially delighted to announce a new partnership between YC and Ginkgo.
Ginkgo Bioworks programs cells. They program them to produce flavors, fragra... |
| 05.08.2019 | How Biotech Startup Funding Will Change in the Next 10 Years | Back when YC was getting started about 10 years ago, Paul Graham wrote some essays that predicted the way startup fundraising would change in the next decade – accurately, it turns out. Paul Graham predicted that there would be way more sta... |
| 24.06.2019 | Atomwise, Enamine Launches AI-Powered 10 Billion Compound Virtual Drug Screen for Pediatric Oncology | Atomwise announced the launch of a 10 billion compound AI-powered virtual drug screening initiative for pediatric oncology, in collaboration with Enamine Ltd., the world’s largest chemical supplier. The goal of this initiative – called the ... |
| 29.04.2019 | YC Partners With Atomwise to Fund More Bio Companies | In the last 10 years, the tools for studying biology have become much less expensive and more widely available. This has made it possible for new startups to do serious research right from the start, and it is leading to an explosion of bio... |
| 12.11.2018 | Y Combinator is Hiring a Visiting Partner in the Life Sciences | YC started funding bio companies in 2011 and since then the number of bio companies we’ve funded per batch has risen exponentially, now over 141 in total. The most recent batch was 25% bio, by far the highest ever. Some of the notable life ... |
| 17.10.2018 | Q&A with Abraham Heifets, Cofounder of Atomwise | We put together a list of the top YC companies by valuation as of October 2018. You can see that list at https://ycombinator.com/topcompanies.
Here’s a Q&A with Abraham Heifets, Cofounder of Atomwise, one of the companies featured on t... |
| 26.04.2018 | Monsanto’s Venture Arm Could Be Winding Down, Sources Suggest, As Company Looks for New Talent | *Updated April 27, 2018, 15:35 to add more context around future of MGV.*
Monsanto Growth Ventures (MGV), the venture arm of Monsanto, has lost all of its dedicated staff after former managing director John Hamer, former investment director... |
| 26.03.2018 | This is how AI will shape drug discovery | An oft-quoted statistic is that it takes 12 years and almost $2 billion dollars to bring an average drug to market. That is the raison d’être for the biotech VC industry, which saw $10 billion of capital invested in startups in 2017 alone, ... |
| 08.03.2018 | Atomwise snags $45M Series A | Drug Delivery | San Francisco, CA | Series A
Founded in 2012, Atomwise leverages AI to discover new medicines and agricultural compounds. The company, which has reportedly raised about $50 million to date, has been valued at $150 million wi... |
| 08.03.2018 | HIMSS18 Day 3 Coverage Highlights & Summary | Inovalon to Acquire ABILITY Network for $1.2B
Inovalon, a technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-based models has acquired ABILITY Network (“ABILITY”) ... |
| 07.03.2018 | Atomwise Raises $45M in Series A Funding | Atomwise, Inc., a San Francisco, CA-based AI driven medicine developer, raised $45m in Series A funding.
The round, which brings total capital raised to more than $51m, was led by Monsanto Growth Ventures, DCVC (Data Collective), and B Capi... |
| 07.03.2018 | Atomwise Raises $45M Series A |
SAN FRANCISCO, CA, Atomwise Inc. today announced it has raised $45 million of growth funding, led by Monsanto Growth Ventures, DCVC (Data Collective), and B Capital Group.
>> Click here for more funding data on Atomwise
>> T... |
| 07.03.2018 | Term Sheet — Wednesday, March 7 | 5 Qs WITH A DEALMAKER
Patricia Nakache, a general partner at Trinity Ventures, calls her path to venture capital “serendipitous.” In 1999, she had recently left McKinsey & Company to join a startup at the peak of the dot-com boom.
Paid ... |
| 07.03.2018 | Atomwise Raises $45M for Artificial Intelligence Platform for Drug Discovery | Atomwise, a San Francisco, CA-based company that develops artificial intelligence systems for drug discovery has raised $45 million in Series A funding led by Monsanto Growth Ventures, B Capital Group and Data Collective. Prior investors Y ... |
| 07.03.2018 | Atomwise, which uses AI to improve drug discovery, raises $45M Series A | Atomwise, which uses deep learning to shorten the process of discovering new drugs, has raised a $45 million Series A. The round was led by Monsanto Growth Ventures, Data Collective (DCVC) and B Capital Group. Baidu Ventures, Tencent and Do... |
| 07.03.2018 | Atomwise Raises $45 Million Series A | - |
| 16.06.2017 | Ag Industry Brief: Amazon Buys Whole Foods, Monsanto & Atomwise Partner to Use AI for Discovery, MidWest Accelerators Announce Investments, more | Amazon is Buying Whole Foods for $13.4bn
Amazon has agreed to buy the upscale grocery chain Whole Foods for $13.4 billion, as the online retailer looks to conquer new territory in the supermarket aisle and bolster its own food delivery serv... |
| 19.04.2017 | Atomwise launches research program to accelerate drug discovery with AI | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Atomwise, which uses artificial intelligence (AI)... |
| 19.04.2017 | Atomwise launches research program to accelerate drug discovery with AI | Atomwise, which uses artificial intelligence (AI) to accelerate drug discovery for diseases like Ebola, multiple sclerosis, and leukemia, today announced the launch of its Artificial Intelligence Molecular Screen (AIMS) program. The program... |
| 16.03.2017 | Advances in AI and ML are reshaping healthcare | Megh Gupta Contributor
Megh Gupta is a member of the investment team at OMERS Ventures.
Qasim Mohammad Contributor
Qasim Mohammad is a Toronto-based venture capitalist and a member of the investment team at OMERS Ventures.
More posts by thi... |
| 29.09.2016 | Hard Tech Startups | Some people think YC only funds straightforward software startups. That’s definitely not the case — YC’s largest exit to date is a self-driving car company, Cruise Automation, and we’ve funded many other hard technology companies like Gingk... |
| 21.07.2016 | Artificial Intelligence Investments Have Tripled Since 2013 | Just a few short years ago, artificial intelligence was seen as nothing more than a villain in sci-fi movies. This revolutionary technology was used to insist that innovating too fast can lead to a future of robot overlords and murderous ma... |
| 29.04.2016 | Tall poppy syndrome and the Canadian opportunity | Gideon Hayden Contributor
Gideon Hayden is co-founder and partner at Leaders Fund.
There’s an epidemic in Canada. That epidemic is a mentality that leaves top talent with no option but to flee the nation’s borders and take with them everyth... |
| 29.02.2016 | Как ИТ-гиганты создают искусственный интеллект | С 2010 года технологии искусственного интеллекта и машинного обучения привлекают всё больше внимания инвесторов и предпринимателей. ИИ-системы уже помогают людям в повседневной жизни, однако пока помощники с цифровым «разумом» не могут выпо... |
| 21.11.2015 | Take a memo, Andreessen Horowitz: 4 areas where it should consider investments | Other investments include Benchling, which develops collaborative tools for life science research, Glow, an ovulation tracking app developer, and Omada Health.
It also invested in Massive Health, a company founded in 2010 that helped diabet... |
| 04.06.2015 | Atomwise Raises $6 Million | Atomwise Inc., a San Francisco, California-based developer of artificial intelligence systems for drug discovery, raised $6m in seed funding.
Backers included Data Collective, which led the funding, Khosla Ventures, DFJ, AME Cloud Ventures,... |
| 04.06.2015 | Medtronic highlights evolving diabetes strategy, Astellas pairs with Swiss biotech in $760M deal (Morning Read) | Japanese drugmaker Astellas and a Swiss biotech startup Anokion are teaming up to launch a joint venture promising up to $760 million with an option to buy the new company. The new venture, Kanyos Bio, will focus on autoimmune disease, usin... |
| 03.06.2015 | Y Combinator Alum Atomwise Raises $6M for AI in Drug Creation | The San Francisco, CA-based Atomwise, which is utilizing artificial intelligence and machine learning to lower the costs and failures associated with discovering and creating new drugs, announced this morning that it has raised $6 million i... |
| 03.06.2015 | Daily funding roundup - June 3, 2015 | Fourkites raised $1.25M; Plot.ly landed $30M; Mic nabbed $17M
Chicago-based FourKites, a provider of trucking logistics for shipping companies and freight brokers, landed $1.25 million in seed funding, its first round since being founded in... |
| 03.06.2015 | Atomwise Raises $6M |
SAN FRANCISCO, CA, According to TC, Drug discovery platform Atomwise has raised $6 million in seed funding.
>> Click here for more funding data on Atomwise
>> To export Atomwise funding data to PDF and Excel, click here
D... |
| 03.06.2015 | YC Alum Atomwise Raises $6 Million To Further The Advancement Of Artificial Intelligence In Drug Discovery | Drug discovery platform Atomwise has raised $6 million in seed funding to dig deeper into artificial intelligence and potentially speed up the process in which we discover new drugs.
The funding came from VC firms that all have some sort of... |
| 03.06.2015 | Funding Daily: Today’s tech funding news, in one place | Here’s a list of today’s tech funding stories, updated as the day unfolds. Tip us here if you have a deal to share. Korea’s Coupang raises $1B from SoftBank in world’s largest round so far in 2015
Your latest reminder that the startup world... |
| 03.06.2015 | Y Combinator-backed Atomwise scores $6M to use deep learning for drug discovery | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Atomwise, a startup that relies on an increasingl... |
| 03.06.2015 | Funding Daily: Today’s tech funding news, in one place | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Here’s a list of today’s tech funding stories, up... |
| 03.06.2015 | Y Combinator-backed Atomwise scores $6M to use deep learning for drug discovery | Atomwise, a startup that relies on an increasingly popular type of artificial intelligence called deep learning to identify drug candidates, announced today a $6 million round of funding.
The promise of Atomwise lies in its algorithms. Inst... |
| 06.05.2015 | Все стартапы последнего выпуска Y Combinator, ФРИИ, Techstars и Tolstoy Startup Camp Статьи редакции | Редакция ЦП собрала в одном материале все стартапы, которые были представлены на последнем Demo Day стартап-акселераторов Y Combinator, ФРИИ, Techstars и Tolstoy Startup Camp.
Y Combinator
Выпуск — март 2015 года.
Akido Labs — стандартизиро... |
| 25.03.2015 | The Top 10 Startups Of Y Combinator Winter ’15 Demo Day 2 | Y Combinator unveiled one of its most impressive startup batches to date yesterday, featuring big ideas in medicine, finance, and marketplaces. After carefully watching the demos, speaking with founders in the class, and querying prestigiou... |
| 24.03.2015 | 47 Startups That Launched At Y Combinator Winter 2015 Demo Day 2 | Y Combinator got so big, it had to split its Demo Day in two. During today’s second wave we saw a variety of promising biotech, marketplace, enterprise, and financial tech startups. Yesterday we chronicled 50 consumer, B2B, developer, and h... |
| 10.03.2015 | YC-Backed Notable Labs Provides Personalized Medical Testing For Brain Cancer Patients | Matt De Silva was working as a hedge fund manager with Thiel Capital in the fall of 2013 when he got the news that his dad had brain cancer — specifically, a Glioblastoma multiforme, an aggressive form of brain cancer.
There are very few tr... |
| 06.03.2015 | Atomwise (YC W15) Discovers Drugs For Diseases That Don’t Even Exist Yet | “Here I am just sitting in this house and I’m able to predict a cure to measles,” co-founder of Atomwise Alex Levy tells me over the phone from his apartment in Mountain View, Calif.
Atomwise, a health tech startup in the current Y Combina... |
| 06.03.2015 | YC-Backed Atomwise Discovers Drugs For Diseases That Don’t Even Exist Yet | “Here I am just sitting in this house and I’m able to predict a cure to measles,” co-founder of Atomwise Alex Levy tells me over the phone from his apartment in Mountain View, Calif.
Atomwise, a health tech startup in the current Y Combinat... |
| - | Take a memo, Andreessen Horowitz: 4 areas where it should consider investments | This week, Andreessen Horowitz said it’s launching a fund dedicated to investments in bioinformatics and “beyond the pill” technology. The venture capital firm had already gotten its feet wet with investments in these areas, but a dedicated... |
| - | With AI we can move into uncharted territory for drug discovery and solve the impossible targets | By Abraham Heifets, CEO of Atomwise
Undrugged genes represent 96 percent of the human genome and include the most challenging — and the most promising — future for pharma and human health. Of the roughly 20,000 proteins encoded in the human... |
| - | How Biotech Startup Funding Will Change in the Next 10 Years | Back when YC was getting started about 10 years ago, Paul Graham wrote some essays that predicted the way startup fundraising would change in the next decade - accurately, it turns out. Paul Graham predicted that there would be way more sta... |
| - | Medtronic highlights evolving diabetes strategy, Astellas pairs with Swiss biotech in $760M deal (Morning Read) | TOP STORY
This week Medtronic highlighted its continuing, evolving interest in diabetes technology. Chief Financial Officer Gary Ellis on a conference call pointed to some recent examples. He noted its minority stake in Glooko and its partn... |
| - | Atomwise Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021 | SAN FRANCISCO--(BUSINESS WIRE)--Mar 9, 2021--
Atomwise, a leader in using artificial intelligence (AI) for small-molecule drug discovery, today announced it has been named to Fast Company's prestigious annual list of the World's Most Innova... |
| - | This is how AI will shape drug discovery | As healthcare venture capitalists, we specialize in technologies that have the potential to transform large markets in healthcare. Earlier this year, we predicted that 2018 would be a year of venture and M&A activity across the pharma v... |
| - | YC and Hard Tech Startups | Some people think YC only funds straightforward software startups. That’s definitely not the case — YC’s largest exit to date is a self-driving car company, Cruise Automation, and we’ve funded many other hard technology companies like Gingk... |
| - | Atomwise | “Our AI superplatform explores chemical space for novel molecules, enhancing drug discovery using machine learning to uncover unseen potential.” |
